Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 1;10(1):3.
doi: 10.1186/s40794-023-00210-z.

A phase II clinical trial of a Vi-DT typhoid conjugate vaccine in healthy Indonesian adolescents and adults: one-month evaluation of safety and immunogenicity

Sukamto Koesnoe  1 , Bernie Endyarni Medise  2 , Iris Rengganis  1 , Sri Rezeki Hadinegoro  3 , Mita Puspita  4 , Rini Mulia Sari  4 , Jae Seung Yang  5 , Sushant Sahastrabuddhe  5 , Soedjatmiko  3 , Hartono Gunardi  3 , Rini Sekartini  3 , Angga Wirahmadi  3 , Aria Kekalih  6 , Sreshta Mukhi  3 , Hindra Irawan Satari  3 , Novilia Sjafri Bachtiar  4
Affiliations

A phase II clinical trial of a Vi-DT typhoid conjugate vaccine in healthy Indonesian adolescents and adults: one-month evaluation of safety and immunogenicity

Sukamto Koesnoe et al. Trop Dis Travel Med Vaccines. .

Abstract

Background: Typhoid fever is commonly found until today, especially in developing countries. It has fatal complications and measures must be taken to reduce the incidence of typhoid. Vaccinations are a key factor in prevention. This is a phase II randomized observer-blind clinical trial on a novel Vi-DT conjugate vaccine on 200 subjects 12 to 40 years of age.

Methods: Subjects were screened for eligibility after which a blood sample was taken and one dose of vaccine was administered. Investigational vaccine used was Vi-DT and control was Vi-PS. Twenty-eight days after vaccination, subjects visited for providing blood sample to assess immunogenicity and were asked about local and systemic adverse reactions that occurred in the first 28 days.

Results: Subjects had minor adverse reactions. Pain was the most common local reaction. Muscle pain was the most common systemic reaction. There were no serious adverse events up to 28 days post vaccination. Seroconversion rates were 100% in the Vi-DT group and 95.96% in the Vi-PS group. Post vaccination GMTs were increased in both groups but it was significantly higher in the Vi-DT group (p < 0.001).

Conclusions: Vi-DT typhoid conjugate vaccine is safe and immunogenic in healthy Indonesian subjects 12 to 40 years.

Trial registration: Approved by ClinicalTrials.gov.

Clinical trial registration number: NCT03460405. Registered on 09/03/2018. URL: https://clinicaltrials.gov/ct2/show/NCT03460405 .

Keywords: Typhoid Fever; Typhoid conjugate vaccine; Vi-DT; Vi-PS.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Study flowchart
See this image and copyright information in PMC

References

    1. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid Fever. N Engl J Med. 2002;347(22):1770–82. doi: 10.1056/NEJMra020201. - DOI - PubMed
    1. Crump JA. Progress in typhoid fever epidemiology. Clin Infect Dis 2019;68(Suppl 1): S4-9.10.1093/cid/ciy846 pmid: 30767000. - PMC - PubMed
    1. Luby SP. Urban slums: a supportive ecosytem for typhoidal salmonellae. J Infect Dis. 2018;218(suppl4):250–4. doi: 10.1093/infdis/jiy324pmid. - DOI - PMC - PubMed
    1. Basnyat B, Qamar F, Rupali P, Ahmed T, Parry C. Clinical update: enteric Fever. BMJ 2021;372: n437 | doi: 10.1136/bmj. n437. - PMC - PubMed
    1. Boggild AK, Castelli F, Gautret P, Torresi J, von Sonnenburg F, Barnett ED, Greenaway CA, Lim PL, Schwartz E, Wilder-Smith A, et al. Vaccine preventable Diseases in returned international travelers: results from the GeoSentinel surveillance network. Vaccine. 2010;28:7389–95. doi: 10.1016/j.vaccine.2010.09.009. - DOI - PubMed

Associated data